Merge Technologies has signed a letter of intent to acquire Interpra Medical Imaging, a Toronto, Ontario-based developer of Java-based clinical workflow and information management software. Merge plans to offer Interpra’s products directly to end
Merge Technologies has signed a letter of intent to acquire Interpra Medical Imaging, a Toronto, Ontario-based developer of Java-based clinical workflow and information management software. Merge plans to offer Interpras products directly to end users as well as through its OEM/VAR channels. Interpra president and chief medical officer Dr. Stephen Herman will stay on as Merges chief medical officer.
The stock-for-stock transaction is expected to be completed by the end of August, subject to the execution of a definitive agreement, completion of due diligence, regulatory approvals, and closing conditions. Interpra shareholders would receive 420,000 shares of Merge stock, along with an equal number of put options exercisable in five years for $4.50 each. Merges stock closed at $1.44 per share on July 27.
In other Merge news, the Milwaukee-based company posted a revenue increase of 47% during its second quarter (end-June). Revenues were $2.8 million, compared with $1.9 million for the same period in 1998. Merge recorded a net loss of $584,000, compared with a net loss of $683,000 last year. Merges results were below analysts expectations, however.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.